Results 71 to 80 of about 5,090 (179)

A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma

Cancer, Volume 132, Issue 4, 15 February 2026.
Abstract Background Pembrolizumab is approved for advanced cutaneous melanoma (aCM). Cabozantinib, an oral multi‐tyrosine kinase inhibitor, has demonstrated antitumor activity as monotherapy or in combination with anti‐PD‐1 therapy in malignancies. The objective of this study was to determine the safety and efficacy of cabozantinib and pembrolizumab ...
Yousef Zakharia, Donghyun Kim, Michele Freesmeier, Melanie Frees, Sarah Mott, Varun Monga, Douglas Laux, Asad Javed, John Rieth, John Smestad, Mohammed Milhem   +10 more
wiley   +1 more source

Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials

Journal for ImmunoTherapy of Cancer, 2017
Background Traditional response criteria may be insufficient to characterize full clinical benefits of anticancer immunotherapies. Consequently, endpoints such as durable response rate (DRR; a continuous response [complete or partial objective response ...
Howard L. Kaufman, Robert H. I. Andtbacka, Frances A. Collichio, Michael Wolf, Zhongyun Zhao, Mark Shilkrut, Igor Puzanov, Merrick Ross   +7 more
doaj   +1 more source

Crosstalk Between Intratumoral Microbes and Tumor Immunity: Implications for Tumor Therapy

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Background Emerging studies indicate that microbes are present in tumor cells and immune cells. Intratumoral microbiota (ITM) constitute an important component of the tumor immune microenvironment (TIME) and have an important impact on tumor progression and treatment. Objective Through the general elaboration of ITM represented by bacteria and
Fengxue Li, Lili Qiao, Xinquan Liang, Yingying Zhang, Ning Liang, Jian Xie, Guodong Deng, Yuying Hao, Pingping Hu, Xue Wu, Fangjie Ding, Can Feng, Yiming Mu, Jiandong Zhang   +13 more
wiley   +1 more source

Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2)

Melanoma Management, 2020
Aim: Talimogene laherparepvec (T-VEC) is an intralesional therapy for unresectable, metastatic melanoma. T-VEC real-world use in the context of anti-PD1-based therapy requires further characterization. Materials & methods: A retrospective review of T-VEC
James Sun, Brian R Gastman, Lucy McCahon, Elizabeth I Buchbinder, Igor Puzanov, Michele Nanni, James M Lewis, Richard D Carvajal, Shahnaz Singh-Kandah, Anupam M Desai, Leon Raskin, Carrie M Nielson, Rubina Ismail, Jonathan S Zager   +13 more
doaj   +1 more source

Induced Vitiligo due to Talimogene Laherparepvec Injection for Metastatic Melanoma Associated with Long-term Complete Response [PDF]

, 2020
Talimogene laherparepvec (T-VEC) (Imlygic, Amgen) is the first oncolytic virus approved for use in therapy for metastatic melanoma. T-VEC provides a treatment option for patients with limited metastatic disease.
Barreiro Capurro, Alicia, Carrera Álvarez, Cristina, Iglesias, Pablo, Malvehy, J. (Josep), Podlipnik, Sebastian, Puig i Sardà, Susana, Ribero, Simone   +6 more
core   +1 more source

Identification of TPRA1 as a Novel Receptor and Predictive Biomarker for Oncolytic Virus M1

Advanced Science, Volume 12, Issue 48, December 29, 2025.
This study identifies transmembrane protein adipocyte‐associated 1 (TPRA1) as a novel receptor for oncolytic virus M1 (OVM). TPRA1's ectodomain binds OVM particles, while its intracellular domain facilitates virus internalization, promoting efficient viral entry.
Linyi Hu, Guigen Zhang, Yuan Lin, Shiming Yi, Jingyu Yang, Xueying Lin, Deli Song, Zhiheng Liu, Jiayu Zhang, Ying Zeng, Shanyu Huang, Zhen Fan, Jifu Zhang, Ying Liu, Cheng Hu, Wenbo Zhu, Wei Yin, Jun Hu, Guangmei Yan, Jing Cai, Jiankai Liang   +20 more
wiley   +1 more source

Talimogene-laherparepvec [PDF]

Reactions Weekly, 2020
  +5 more sources

Aseptic Sinusitis: A New Phenotype of Immune‐Related Rhinosinusitis in the Era of Immune Checkpoint Inhibitors

Clinical Case Reports, Volume 13, Issue 12, December 2025.
(A‐B) Patient 1 CT Imaging of sinuses before (A) and after (B) completing 2 months of steroid therapy for immune‐mediated sinusitis. ABSTRACT We present two novel cases of aseptic sinusitis resulting from PDL‐1 checkpoint inhibitor use. Prompt identification and diagnosis and a multidisciplinary approach with oncology and rheumatology are imperative ...
Josephine Yalovitser, Kenny Nguyen, Kelly McKenna, Shahid Ahmed, Carolyn Orgain   +4 more
wiley   +1 more source

Reprogramming the tumour microenvironment: Emerging strategies to overcome immunotherapy resistance

Clinical and Translational Discovery, Volume 5, Issue 6, December 2025.
Reprogramming the tumour microenvironment (TME) overcomes immunotherapy resistance by targeting immunosuppressive cells, abnormal vasculature and metabolic dysregulation. Emerging strategies, including epigenetic modulation, vascular normalisation and cellular therapies, transform the TME into an immune‐active landscape, enhancing T‐cell infiltration ...
Mohammed Elmujtba Adam Essa, Shahd Elbadri, Abdelkareem A. Ahmed, Hamid Noori   +3 more
wiley   +1 more source

Immunotherapeutic potential of oncolytic vaccinia virus [PDF]

, 2014
The concept of oncolytic viral therapy was based on the hypothesis that engineering tumor-selectivity into the replication potential of viruses would permit direct destruction of tumor cells as a result of viral-mediated lysis, resulting in amplification
Thorne, SH
core   +1 more source